{"id":3083,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2002-06-04","marketCap":119.476,"name":"Capricor Therapeutics Inc","phone":"13103583200","outstanding":30.79,"symbol":"CAPR","website":"https://capricor.com/","industry":"Biotechnology"},"price":5.4325,"year":2024,"month":3,"day":9,"weekday":"Saturday","title":"Ownership Structure of Capricor Therapeutics Inc","date":"2024-03-09","url":"/posts/2024/03/09/CAPR","content":[{"section":"Institutional Investors","text":"As of the latest filing, institutional investors hold approximately 32.47% of Capricor Therapeutics Inc stock. The top institutional shareholders are BlackRock Inc with a 7.89% stake, Vanguard Group Inc with a 6.82% stake, and State Street Corporation with a 4.61% stake."},{"section":"Insider Ownership","text":"Insider ownership of Capricor Therapeutics Inc stands at approximately 10.62%. The major insiders include the CEO, Linda Marbán, who holds a 2.05% stake, and other key executives and board members."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1709823306,"headline":"Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?","id":126393348,"image":"https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","symbol":"CAPR","publisher":"Yahoo","summary":"The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.","url":"https://finance.yahoo.com/news/capricor-capr-climb-261-27-145506969.html"},{"category":"company","date":1709731800,"headline":"Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical \u0026 Scientific Conference","id":126352050,"image":"https://media.zenfs.com/en/globenewswire.com/0e4aa7c149c226fb6476bc33145e6f66","symbol":"CAPR","publisher":"Yahoo","summary":"Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-10","url":"https://finance.yahoo.com/news/capricor-therapeutics-presents-2024-muscular-133000852.html"},{"category":"company","date":1709710860,"headline":"Capricor Therapeutics presents results from HOPE-2 extension study","id":126368554,"image":"","symbol":"CAPR","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3384549279"},{"category":"company","date":1709639760,"headline":"Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress","id":126342241,"image":"","symbol":"CAPR","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3383063842"},{"category":"company","date":1709633400,"headline":"Regenxbio stock jumps 13% on positive data for DMD drug","id":126329860,"image":"","symbol":"CAPR","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3382923292"},{"category":"company","date":1709469701,"headline":"Capricor Therapeutics Full Year 2023 Earnings: Beats Expectations","id":126277316,"image":"https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","symbol":"CAPR","publisher":"Yahoo","summary":"Capricor Therapeutics ( NASDAQ:CAPR ) Full Year 2023 Results Key Financial Results Revenue: US$25.2m (up by US$22.6m...","url":"https://finance.yahoo.com/news/capricor-therapeutics-full-2023-earnings-124141502.html"},{"category":"company","date":1709385438,"headline":"Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript","id":126269619,"image":"https://s.yimg.com/ny/api/res/1.2/cdjyVVO8ZUYmIO6uOS5yzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/22e93ca7d4fe1fce85b80d0d968ae7ff","symbol":"CAPR","publisher":"Yahoo","summary":"Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript February 29, 2024 Capricor Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.23. Capricor Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]","url":"https://finance.yahoo.com/news/capricor-therapeutics-inc-nasdaq-capr-131718580.html"},{"category":"company","date":1709291187,"headline":"Q4 2023 Capricor Therapeutics Inc Earnings Call","id":126235226,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"CAPR","publisher":"Yahoo","summary":"Q4 2023 Capricor Therapeutics Inc Earnings Call","url":"https://finance.yahoo.com/news/q4-2023-capricor-therapeutics-inc-110627736.html"},{"category":"company","date":1709270460,"headline":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)","id":126247334,"image":"","symbol":"CAPR","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3376576389"},{"category":"company","date":1709248443,"headline":"Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript","id":126219795,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"CAPR","publisher":"SeekingAlpha","summary":"Capricor Therapeutics, Inc. (NASDAQ:NASDAQ:CAPR) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ETCompany ParticipantsAJ Bergmann - Chief...","url":"https://seekingalpha.com/article/4675154-capricor-therapeutics-inc-capr-q4-2023-earnings-call-transcript"},{"category":"company","date":1709242942,"headline":"Capricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapy","id":126214212,"image":"https://s.yimg.com/ny/api/res/1.2/.buUdZAvzyihhWBPr7EAeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01Mzg-/https://media.zenfs.com/en/us.finance.gurufocus/0ab417ffd29ee909c4cd814737e85026","symbol":"CAPR","publisher":"Yahoo","summary":"Company Poised for Pivotal Trial Results and FDA Discussions in 2024","url":"https://finance.yahoo.com/news/capricor-therapeutics-inc-capr-reports-214222359.html"},{"category":"company","date":1709240700,"headline":"Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update","id":126214214,"image":"https://media.zenfs.com/en/globenewswire.com/0e4aa7c149c226fb6476bc33145e6f66","symbol":"CAPR","publisher":"Yahoo","summary":"-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 2024- -Upcoming Type-B Meeting with FDA in Q1 2024 to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy- -CAP-1002 Scale-Up Expansion Underway at New San Diego Manufacturing Facility in Preparation for Commercial Launch- -Plan to","url":"https://finance.yahoo.com/news/capricor-therapeutics-reports-fourth-quarter-210500076.html"},{"category":"company","date":1709224570,"headline":"Capricor: Q4 Earnings Snapshot","id":126208264,"image":"","symbol":"CAPR","publisher":"Finnhub","summary":"SAN DIEGO — SAN DIEGO — Capricor Therapeutics Inc. on Thursday reported a loss of $762,000 in its fourth quarter. The San Diego-based company said it had a loss of 2 cents per share. ...","url":"https://finnhub.io/api/news?id=e8bebf7d2e91051c764a2c9c1fd9aa27d6fa5388b580210baae484d0a111fce1"},{"category":"company","date":1709180280,"headline":"Earnings Scheduled For February 29, 2024","id":126197860,"image":"","symbol":"CAPR","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3374231306"},{"category":"company","date":1709177400,"headline":"Recap: Capricor Therapeutics Q4 Earnings","id":126217041,"image":"","symbol":"CAPR","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3375297445"},{"category":"company","date":1709176920,"headline":"Capricor Therapeutics reports Q4 EPS (2c), consensus (9c)","id":126217042,"image":"","symbol":"CAPR","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3375279339"},{"category":"company","date":1709176860,"headline":"Capricor Therapeutics GAAP EPS of -$0.02 beats by $0.18, revenue of $12.08M beats by $1.48M","id":126217043,"image":"","symbol":"CAPR","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3375276335"},{"category":"company","date":1709118180,"headline":"Capricor Therapeutics's Earnings Outlook","id":126217044,"image":"","symbol":"CAPR","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3372569409"},{"category":"company","date":1709095140,"headline":"Capricor Therapeutics Q4 2023 Earnings Preview","id":126217045,"image":"","symbol":"CAPR","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3373172972"},{"category":"company","date":1709040600,"headline":"Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy","id":126171238,"image":"https://media.zenfs.com/en/globenewswire.com/0e4aa7c149c226fb6476bc33145e6f66","symbol":"CAPR","publisher":"Yahoo","summary":"SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food \u0026 Drug Administration (FDA) scheduled for late March. In the upcoming meeting with the FDA, the Company intends to discuss its proposed chemistry, manufacturing and controls (CMC) p","url":"https://finance.yahoo.com/news/capricor-therapeutics-announces-upcoming-type-133000802.html"},{"category":"company","date":1709035740,"headline":"Capricor Therapeutics Shares Rise 8% After FDA Meeting Set","id":126175347,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"CAPR","publisher":"MarketWatch","summary":"By Chris Wack Capricor Therapeutics shares were up 8%, to $4.29, after the biotechnology company said it has been granted an in-person Type-B meeting with...","url":"https://www.marketwatch.com/story/capricor-therapeutics-shares-rise-8-after-fda-meeting-set-04f17a47"},{"category":"company","date":1709019480,"headline":"Capricor announces company granted in-person Type-B meeting with FDA","id":126166500,"image":"","symbol":"CAPR","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3370138913"}]}